TBC1D12
gene geneOn this page
Also known as KIAA0608
Summary
TBC1D12 (TBC1 domain family member 12, HGNC:29082) is a protein-coding gene on chromosome 10q23.33, encoding TBC1 domain family member 12 (O60347). RAB11A-binding protein that plays a role in neurite outgrowth.
Predicted to enable GTPase activator activity. Predicted to be involved in regulation of autophagosome assembly. Predicted to be located in endosome. Predicted to be active in autophagosome and recycling endosome.
Source: NCBI Gene 23232 — RefSeq curated summary.
At a glance
- GWAS associations: 9
- Clinical variants (ClinVar): 79 total
- MANE Select transcript:
NM_015188
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:29082 |
| Approved symbol | TBC1D12 |
| Name | TBC1 domain family member 12 |
| Location | 10q23.33 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA0608 |
| Ensembl gene | ENSG00000108239 |
| Ensembl biotype | protein_coding |
| OMIM | 620003 |
| Entrez | 23232 |
Gene structure
Transcript identifiers
Ensembl transcripts: 12 — 10 protein_coding, 2 protein_coding_CDS_not_defined
ENST00000225235, ENST00000457045, ENST00000485048, ENST00000904398, ENST00000904399, ENST00000904400, ENST00000904401, ENST00000904402, ENST00000904403, ENST00000971287, ENST00000971288, ENST00000971289
RefSeq mRNA: 1 — MANE Select: NM_015188
NM_015188
CCDS: CCDS41553
Canonical transcript exons
ENST00000225235 — 13 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000715888 | 94441896 | 94442019 |
| ENSE00000810844 | 94493365 | 94493447 |
| ENSE00000810845 | 94497055 | 94497172 |
| ENSE00000810846 | 94500221 | 94500327 |
| ENSE00000810847 | 94507267 | 94507347 |
| ENSE00000810850 | 94521955 | 94522083 |
| ENSE00000810851 | 94522344 | 94522453 |
| ENSE00000933023 | 94474668 | 94474783 |
| ENSE00001021609 | 94402541 | 94403584 |
| ENSE00001162241 | 94533028 | 94536332 |
| ENSE00001272582 | 94510091 | 94510179 |
| ENSE00003550909 | 94531202 | 94531460 |
| ENSE00003598898 | 94511583 | 94511654 |
Expression profiles
Bgee: expression breadth ubiquitous, 268 present calls, max score 95.12.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5766 / max 162.8225, expressed in 1596 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 106318 | 1.7939 | 857 |
| 106317 | 1.6512 | 933 |
| 106316 | 1.5441 | 916 |
| 106319 | 0.5874 | 292 |
Top tissues by expression
289 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| C1 segment of cervical spinal cord | UBERON:0006469 | 95.12 | gold quality |
| spinal cord | UBERON:0002240 | 94.22 | gold quality |
| corpus callosum | UBERON:0002336 | 92.75 | gold quality |
| inferior olivary complex | UBERON:0002127 | 91.24 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 90.46 | gold quality |
| medial globus pallidus | UBERON:0002477 | 88.41 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 88.12 | gold quality |
| substantia nigra | UBERON:0002038 | 88.04 | gold quality |
| dorsal motor nucleus of vagus nerve | UBERON:0002870 | 87.76 | gold quality |
| midbrain | UBERON:0001891 | 87.33 | gold quality |
| tibia | UBERON:0000979 | 87.31 | gold quality |
| globus pallidus | UBERON:0001875 | 87.27 | gold quality |
| medulla oblongata | UBERON:0001896 | 86.28 | gold quality |
| jejunal mucosa | UBERON:0000399 | 85.06 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 84.97 | gold quality |
| calcaneal tendon | UBERON:0003701 | 84.62 | gold quality |
| Ammon’s horn | UBERON:0001954 | 84.24 | gold quality |
| cortical plate | UBERON:0005343 | 83.88 | gold quality |
| visceral pleura | UBERON:0002401 | 83.42 | gold quality |
| pons | UBERON:0000988 | 83.06 | gold quality |
| parietal pleura | UBERON:0002400 | 83.05 | gold quality |
| pleura | UBERON:0000977 | 82.89 | gold quality |
| hypothalamus | UBERON:0001898 | 82.89 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 82.87 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 82.49 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 82.34 | gold quality |
| putamen | UBERON:0001874 | 82.26 | gold quality |
| primary visual cortex | UBERON:0002436 | 81.80 | gold quality |
| ventricular zone | UBERON:0003053 | 81.80 | gold quality |
| amygdala | UBERON:0001876 | 81.59 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 6.82 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
205 targeting TBC1D12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-200B-3P | 100.00 | 73.31 | 2693 |
| HSA-MIR-200C-3P | 100.00 | 73.35 | 2685 |
| HSA-MIR-429 | 100.00 | 73.44 | 2698 |
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-4481 | 100.00 | 66.42 | 1669 |
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-223-3P | 99.99 | 70.14 | 1140 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-4789-3P | 99.99 | 70.75 | 2484 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-33A-5P | 99.99 | 68.62 | 1055 |
| HSA-MIR-33B-5P | 99.99 | 68.58 | 1062 |
| HSA-MIR-4789-5P | 99.98 | 70.76 | 2721 |
| HSA-MIR-32-5P | 99.98 | 75.21 | 1964 |
| HSA-MIR-92A-3P | 99.98 | 75.21 | 1960 |
| HSA-MIR-92B-3P | 99.98 | 75.25 | 1955 |
| HSA-MIR-25-3P | 99.98 | 74.60 | 1817 |
| HSA-MIR-363-3P | 99.98 | 74.72 | 1821 |
| HSA-MIR-367-3P | 99.98 | 74.83 | 1819 |
| HSA-MIR-4745-5P | 99.98 | 65.95 | 1028 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-103A-3P | 99.98 | 69.14 | 1595 |
| HSA-MIR-107 | 99.98 | 69.14 | 1595 |
| HSA-MIR-4482-3P | 99.98 | 72.50 | 3147 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | tbc1d12b | ENSDARG00000073771 |
| danio_rerio | ENSDARG00000112088 | |
| mus_musculus | Tbc1d12 | ENSMUSG00000048720 |
| rattus_norvegicus | Tbc1d12 | ENSRNOG00000036598 |
Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D2 (ENSG00000095383), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D9 (ENSG00000109436), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), SGSM2 (ENSG00000141258), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3G (ENSG00000260287), TBC1D3K (ENSG00000273513), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3L (ENSG00000274512), TBC1D3 (ENSG00000274611)
Protein
Protein identifiers
TBC1 domain family member 12 — O60347 (reviewed: O60347)
All UniProt accessions (1): O60347
UniProt curated annotations — full annotation on UniProt →
Function. RAB11A-binding protein that plays a role in neurite outgrowth.
Subunit / interactions. Interacts with RAB11A; this interaction recruits TBC1D12 to RAB11A-positive recycling endosomes.
Subcellular location. Endosome.
RefSeq proteins (1): NP_056003* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000195 | Rab-GAP-TBC_dom | Domain |
| IPR035969 | Rab-GAP_TBC_sf | Homologous_superfamily |
| IPR050302 | Rab_GAP_TBC_domain | Family |
Pfam: PF00566
UniProt features (18 total): modified residue 5, compositionally biased region 5, sequence conflict 3, region of interest 2, chain 1, domain 1, coiled-coil region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-O60347-F1 | 64.59 | 0.39 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (5): 1, 284, 315, 747, 748
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 168 (showing top):
GOBP_VACUOLE_ORGANIZATION, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_VACUOLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_MACROAUTOPHAGY, MORF_ZNF10, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_ORGANELLE_ASSEMBLY, MORF_EPHA7, MORF_RAB3A, MORF_BMPR2, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, CUI_TCF21_TARGETS_2_DN, GOBP_REGULATION_OF_ORGANELLE_ASSEMBLY
GO Biological Process (2): vesicle-mediated transport (GO:0016192), regulation of autophagosome assembly (GO:2000785)
GO Molecular Function (2): GTPase activator activity (GO:0005096), enzyme binding (GO:0019899)
GO Cellular Component (5): autophagosome (GO:0005776), recycling endosome (GO:0055037), endosome (GO:0005768), vacuole (GO:0005773), cytoplasmic vesicle (GO:0031410)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoplasm | 2 |
| transport | 1 |
| cellular process | 1 |
| autophagosome assembly | 1 |
| regulation of vacuole organization | 1 |
| regulation of organelle assembly | 1 |
| GTPase activity | 1 |
| enzyme activator activity | 1 |
| GTPase regulator activity | 1 |
| protein binding | 1 |
| vacuole | 1 |
| endosome | 1 |
| endomembrane system | 1 |
| cytoplasmic vesicle | 1 |
| intracellular membrane-bounded organelle | 1 |
| intracellular vesicle | 1 |
Protein interactions and networks
STRING
488 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TBC1D12 | PLEKHS1 | Q5SXH7 | 671 |
| TBC1D12 | LEPROTL1 | O95214 | 615 |
| TBC1D12 | WDR74 | Q6RFH5 | 584 |
| TBC1D12 | TBC1D19 | Q8N5T2 | 546 |
| TBC1D12 | TBC1D21 | Q8IYX1 | 526 |
| TBC1D12 | SGSM2 | O43147 | 519 |
| TBC1D12 | CCDC107 | Q8WV48 | 513 |
| TBC1D12 | TBC1D23 | Q9NUY8 | 509 |
| TBC1D12 | TBC1D13 | Q9NVG8 | 458 |
| TBC1D12 | PLCE1 | Q9P212 | 453 |
| TBC1D12 | C3orf70 | A6NLC5 | 447 |
| TBC1D12 | MB21D2 | Q8IYB1 | 444 |
| TBC1D12 | TBC1D7 | Q9P0N9 | 441 |
| TBC1D12 | FBXO8 | Q9NRD0 | 418 |
| TBC1D12 | CCDC158 | Q5M9N0 | 416 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| Xpo1 | IFT56 | psi-mi:“MI:0914”(association) | 0.350 |
| NEK4 | E2F8 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (15): TBC1D12 (Affinity Capture-MS), TBC1D12 (Synthetic Lethality), TBC1D12 (Proximity Label-MS), TBC1D12 (Affinity Capture-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Affinity Capture-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS), TBC1D12 (Proximity Label-MS)
ESM2 similar proteins: A1A5B6, A6H7I8, A7E300, B9VTT2, F1LXF1, M0R7T9, O08873, O14795, O60347, O60447, P0C6S7, P11274, P22681, P22682, P49797, Q0IHY4, Q0VGY8, Q14432, Q3MII6, Q4KUS2, Q5CD77, Q62769, Q69ZT9, Q6A039, Q6F6B3, Q6P9S0, Q6PAJ1, Q6PCS4, Q6ZM89, Q765P7, Q80U28, Q80YA9, Q8BIZ1, Q8CGA2, Q8K214, Q8R1S4, Q8WXG6, Q8WXI2, Q923Q2, Q92625
Diamond homologs: A6H7I8, M0R7T9, O60347, O96904, Q0IHY4, Q10496, Q5CD77, Q6A039, Q86UD7, Q8CGA2, Q96CN4, Q9P2M4, A2AWA9, Q5RAN1, Q755I4, Q9Y3P9, Q9Y7J5, Q5R372, Q5RCW6, A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A3KGB4, A6H6A9, A6NDS4, A6NER0, A6QP29, B9A6J9, D2H0G5, H2KZZ6, O60343, O95759, O97790, P0C7X1, P35125, P53258, P58802, Q0IIM8, Q28CB1
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
79 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 66 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2876 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 10:94429374:GCC:G | donor_gain | 1.0000 |
| 10:94441891:TTCA:T | acceptor_loss | 1.0000 |
| 10:94441892:TCAG:T | acceptor_loss | 1.0000 |
| 10:94441893:CA:C | acceptor_loss | 1.0000 |
| 10:94441894:A:AG | acceptor_gain | 1.0000 |
| 10:94441894:AG:A | acceptor_loss | 1.0000 |
| 10:94441895:G:GT | acceptor_gain | 1.0000 |
| 10:94441895:GA:G | acceptor_gain | 1.0000 |
| 10:94441895:GAA:G | acceptor_gain | 1.0000 |
| 10:94441895:GAAA:G | acceptor_gain | 1.0000 |
| 10:94441895:GAAAC:G | acceptor_gain | 1.0000 |
| 10:94442015:AGCAG:A | donor_gain | 1.0000 |
| 10:94442016:GCAGG:G | donor_gain | 1.0000 |
| 10:94442017:CAGG:C | donor_loss | 1.0000 |
| 10:94442018:AGG:A | donor_loss | 1.0000 |
| 10:94442020:G:GA | donor_loss | 1.0000 |
| 10:94442020:G:GG | donor_gain | 1.0000 |
| 10:94442021:T:A | donor_loss | 1.0000 |
| 10:94443326:A:G | acceptor_gain | 1.0000 |
| 10:94444438:T:TA | acceptor_gain | 1.0000 |
| 10:94474664:CTAG:C | acceptor_loss | 1.0000 |
| 10:94474666:A:AC | acceptor_loss | 1.0000 |
| 10:94474667:G:GC | acceptor_loss | 1.0000 |
| 10:94474779:CCATC:C | donor_gain | 1.0000 |
| 10:94474780:CATC:C | donor_gain | 1.0000 |
| 10:94474781:ATC:A | donor_gain | 1.0000 |
| 10:94474782:TC:T | donor_gain | 1.0000 |
| 10:94474782:TCGTA:T | donor_loss | 1.0000 |
| 10:94474784:G:GG | donor_gain | 1.0000 |
| 10:94474785:TA:T | donor_loss | 1.0000 |
AlphaMissense
5057 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 10:94474765:T:C | I398T | 1.000 |
| 10:94497138:T:A | W460R | 1.000 |
| 10:94497138:T:C | W460R | 1.000 |
| 10:94500249:T:A | W481R | 1.000 |
| 10:94500249:T:C | W481R | 1.000 |
| 10:94500258:G:A | G484R | 1.000 |
| 10:94500258:G:C | G484R | 1.000 |
| 10:94500259:G:A | G484E | 1.000 |
| 10:94500274:T:A | V489D | 1.000 |
| 10:94500276:C:A | R490S | 1.000 |
| 10:94500277:G:C | R490P | 1.000 |
| 10:94500286:T:A | V493D | 1.000 |
| 10:94500288:T:A | W494R | 1.000 |
| 10:94500288:T:C | W494R | 1.000 |
| 10:94500289:G:C | W494S | 1.000 |
| 10:94500290:G:C | W494C | 1.000 |
| 10:94500290:G:T | W494C | 1.000 |
| 10:94500313:T:C | L502P | 1.000 |
| 10:94507270:T:C | L508P | 1.000 |
| 10:94510130:T:A | I547N | 1.000 |
| 10:94510138:G:C | D550H | 1.000 |
| 10:94510138:G:T | D550Y | 1.000 |
| 10:94510139:A:C | D550A | 1.000 |
| 10:94510139:A:G | D550G | 1.000 |
| 10:94510139:A:T | D550V | 1.000 |
| 10:94510140:C:A | D550E | 1.000 |
| 10:94510140:C:G | D550E | 1.000 |
| 10:94510142:T:A | I551K | 1.000 |
| 10:94510148:G:C | R553P | 1.000 |
| 10:94510151:C:A | T554K | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000013155 (10:94529459 A>C), RS1000023686 (10:94469196 A>G), RS1000036331 (10:94514906 T>C), RS1000044128 (10:94426734 A>G), RS1000045445 (10:94440487 T>C), RS1000076260 (10:94486674 T>C,G), RS1000149877 (10:94401638 C>G), RS1000154262 (10:94445110 C>T), RS1000155208 (10:94498751 C>A), RS1000165897 (10:94536128 G>A,T), RS1000173999 (10:94407399 C>A), RS1000174860 (10:94410751 G>C), RS1000184841 (10:94444752 G>A,T), RS1000220420 (10:94402745 C>T), RS1000230853 (10:94445234 C>G)
Disease associations
OMIM: gene MIM:620003 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
9 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004621_16 | Red cell distribution width | 2.000000e-13 |
| GCST006206_3 | Thiopurine-induced alopecia in inflammatory bowel disease | 1.000000e-06 |
| GCST006804_54 | Red cell distribution width | 6.000000e-13 |
| GCST007684_2 | Plasma clozapine-norclozapine ratio in treatment-resistant schizophrenia | 5.000000e-14 |
| GCST009174_2 | Response to (pegylated) interferon in chronic hepatitis B | 1.000000e-06 |
| GCST010397_80 | Gut microbiota (bacterial taxa, rank normal transformation method) | 7.000000e-06 |
| GCST90002396_490 | Mean reticulocyte volume | 1.000000e-33 |
| GCST90002398_181 | Neutrophil count | 3.000000e-18 |
| GCST90002403_223 | Red blood cell count | 2.000000e-11 |
EFO canonical traits (7, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0009188 | Red cell distribution width |
| EFO:0600040 | plasma clozapine-to-N-desmethylclozapine ratio measurement |
| EFO:0007859 | response to interferon |
| EFO:0007874 | gut microbiome measurement |
| EFO:0010701 | mean reticulocyte volume |
| EFO:0004833 | neutrophil count |
| EFO:0004305 | erythrocyte count |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
34 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | affects cotreatment, decreases expression, increases abundance, increases expression | 2 |
| Valproic Acid | affects expression, increases expression | 2 |
| dicrotophos | decreases expression | 1 |
| methylmercuric chloride | decreases expression | 1 |
| trichostatin A | increases expression | 1 |
| cobaltous chloride | increases expression | 1 |
| butyraldehyde | decreases expression | 1 |
| manganese chloride | decreases expression, increases abundance, affects cotreatment | 1 |
| potassium chromate(VI) | affects cotreatment, decreases expression | 1 |
| epigallocatechin gallate | affects cotreatment, decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| monomethylarsonous acid | increases expression | 1 |
| abrine | increases expression | 1 |
| jinfukang | decreases expression | 1 |
| Resveratrol | affects cotreatment, increases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Arsenic | increases abundance, affects cotreatment, decreases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Folic Acid | decreases expression | 1 |
| Formaldehyde | decreases expression | 1 |
| Hydrogen Peroxide | affects expression | 1 |
| Lead | affects expression | 1 |
| Manganese | decreases expression, increases abundance, affects cotreatment | 1 |
| Melphalan | decreases expression | 1 |
| Plant Extracts | affects cotreatment, increases expression | 1 |
| Thiram | increases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Urethane | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.